Prenatal growth restraint associates with the risk for later diabetes, particularly if such restraint is followed by postnatal formulafeeding (FOF) rather than breast-feeding (BRF). Circulating incretins can influence the neonatal programming of hypothalamic setpoints for appetite and energy expenditure, and are thus candidate mediators of the long-term effects exerted by early nutrition. We have tested this concept by measuring (at birth and at age 4 months) the circulating concentrations of glucagon-like peptide-1 (GLP-1) in BRF infants born appropriate-for-gestational-age (AGA; n = 63) and in small-for-gestational-age (SGA) infants receiving either BRF (n = 28) or FOF (n = 26). At birth, concentrations of GLP-1 were similar in AGA and SGA infants. At 4 months, pre-feeding GLP-1 concentrations were higher than at birth; SGA-BRF infants had GLP-1 concentrations similar to those in AGA-BRF infants but SGA-FOF infants had higher concentrations. In conclusion, nutrition appears to influence the circulating GLP-1 concentrations in SGA infants and may thereby modulate long-term diabetes risk.
INTRODUCTION
Fetal growth restraint is associated with risk of becoming adipose and insulin resistant in childhood 1 and of developing type 2 diabetes in later life. 2, 3 The mediating mechanisms are poorly understood, but neonatal breast-feeding (BRF) is thought to confer long-term protective effects. 4 A decade ago, an impaired effect of the incretin glucagon-like peptide-1 (GLP-1) was suspected as candidate mechanism, but GLP-1 secretion, as well as GLP-1 action on insulin secretion, were found to be normal in young adults with low birth weight. 5 Early infancy is a critical window of neurodevelopmental plasticity, and recent data suggest that neonatally circulating incretins can influence the hypothalamic setpoints of features such as appetite and energy expenditure. [6] [7] [8] [9] We performed a first test of this novel concept in human infants: longitudinally (at birth and at 4 months), we have measured the circulating concentrations of GLP-1 in BRF infants born appropriate-for-gestational-age (AGA) and in small-for-gestational-age (SGA) infants receiving either BRF or formula-feeding (FOF).
MATERIALS AND METHODS

Study population
The study population consisted of 117 term infants (63 AGA-BRF, 28 SGA-BRF and 26 SGA-FOF) who participated in a previously described, longitudinal study of the body composition and the endocrine-metabolic state of SGA infants, as compared with AGA controls. 10 The difference between the original population 10 and the present population ensues from the availability of serum to assess GLP-1 (at birth and at 4 months) and from the prioritization of the three subgroups that are nowadays most relevant for clinical practice ( Supplementary Figure 1) .
Thus, the inclusion criteria for the present report were:
1. Birth at Hospital Sant Joan de Déu, Barcelona, after an uncomplicated, term (37-42 weeks), singleton pregnancy (no maternal hypertension, preeclampsia, gestational diabetes, alcohol abuse or drug addiction). 2. Birth weight between 2.9 and 3.9 kg for AGA (between − 1 s.d. and +1 s.d. for gestational age) and between 1.9 and 2.6 kg for SGA infants (⩽ −2 s.d. for gestational age). 3. Exclusive BRF for 4 months in AGA controls; either exclusive BRF for 4 months, or exclusive FOF (Enfalac 1, Mead Johnson, Glenview, IL, USA) in SGA infants. 4. Auxological assessments at birth and at the age of 2 weeks and at 4 months; endocrine assessments at birth and age 4 months; body-composition assessments at age of 2 weeks and at 4 months. 5. Enough cord serum available (at birth) and enough serum available in pre-feeding state at age 4 months to enable measurement of circulating GLP-1. 6. Written, informed consent in Spanish/Catalan language at birth. Exclusion criteria were: complications at birth (need for resuscitation or for parenteral nutrition) and congenital malformations.
Assessments
As described, 10 weight and length were measured by the same investigator at birth and at 4 months. Weight was measured with a beam balance (Seca, Hamburg, Germany) and length with a length board, the mean of three measurements being used for analysis. Body composition was assessed by absorptiometry at the age of 2 weeks and at 4 months with a Lunar Prodigy, coupled to Lunar software (version 3.4/3.5; Lunar, Madison, WI, USA), adapted for assessment of infants. Bone mineral content, lean mass, as well as total, truncal and abdominal fat mass were assessed during natural sleep; coefficients of variation (CVs) were o3% for lean and fat mass.
Blood was sampled in the morning, in pre-feeding state. Neither a DPP4 inhibitor nor aprotinin were added to the sample. Total serum GLP-1 was assessed by ELISA (Millipore, Billerica, MA, USA). The antibody pair in this assay measures GLP-1 (7-36) and and has no significant cross-reactivity with GLP-2, GIP, glucagon or oxyntomodulin. The intra-and inter-assay CVs were o2% and o10%; the lower detection limit was 1.5 pM. Serum insulin-like growth factor I concentrations were measured by immunochemiluminiscence (IMMULITE 2000, Diagnostic Products, Los Angeles, CA, USA), the detection limit being 25 ng/mL and the intra-and inter-assay CVs o 10%. Serum high-molecular-weight adiponectin was assessed by ELISA with intra-and inter-assay CVs o 9%.
Statistics and ethics
Statistical analyses were performed with IBM SPSS Statistics 19.0 (IBM SPSS, Chicago, IL, USA). Comparisons were performed by two-tailed t-test or Mann-Whitney test, as appropriate; P o 0.05 was considered statistically significant.
The original study was approved by the institutional review board of Barcelona University, Hospital of Sant Joan de Déu; informed written consent was an inclusion criterion. The present manuscript focuses on GLP-1 because other endocrine, auxological and body-composition results have been described. 10 Figure 1 shows that at birth, the circulating concentrations of GLP-1 were readily detectable and similar in AGA and SGA infants. GLP-1 concentrations were also similar in girls and boys. In each study subgroup, GLP-1 levels at 4 months were higher than at Abbreviations: AGA, appropriate-for-gestational-age; BMC, bone mineral content; BMI, body mass index; BRF, breast-fed; FOF, formula-fed; GLP-1, glucagon-like peptide-1; HMW, high molecular weight; IGF-I, insulin-like growth factor I; PI, ponderal index; SGA, small-for-gestational-age. Values are mean ± s.e.m. *Po0.05 versus AGA BRF, **Po0.05 versus SGA BRF. a at age 2 weeks instead of at birth.
RESULTS
Circulating GLP-1 in infants birth. SGA-BRF infants had GLP-1 concentrations at 4 months and GLP-1 increments between birth and 4 months that were comparable to those in AGA-BRF controls. However, SGA-FOF infants had higher GLP-1 concentrations at 4 months and also higher GLP-1 increments than AGA-BRF controls and SGA-BRF infants ( Table 1 shows the numerical results). Positive Spearman correlations (P o0.01) were identified between GLP-1 and insulin-like growth factor I concentrations at 4 months (r = 0.27) and also between changes (0-4 months) of GLP-1 and HMW adiponectin concentrations (r = 0.25).
DISCUSSION
At birth, circulating GLP-1 concentrations were similar in AGA and SGA infants, suggesting that the intestinal transit of amniotic fluid is sufficient (or that no intestinal transit is required) to generate some release of GLP-1 by intestinal L-cells, and that prenatal growth and fetal GLP-1 levels are essentially independent of each other.
At 4 months, in pre-feeding state, the GLP-1 concentrations of BRF infants were about twice as high as at birth. Our study design does not allow to infer when exactly those GLP-1 levels surge, but cross-sectional evidence from newborns aged 4-10 days suggests that this surge (to supra-adult concentrations) occurs within the first few days after birth. 11 The observation that pre-feeding GLP-1 levels are higher in SGA infants receiving FOF than in those receiving BRF during early infancy suggests that neonatal nutrition is a modulator of circulating GLP-1 in SGA infants and is thus a potential modulator of hypothalamic setpoints that relate to appetite and energy expenditure in subsequent life. [6] [7] [8] [9] For example, higher concentrations of circulating GLP-1 during early infancy may be accompanied by lower hypothalamic sensitivity to GLP-1 in later life. Given that SGA-BRF infants follow a less adipose and more favorable endocrine-metabolic course than SGA-FOF infants, 12 circulating GLP-1 may become a helpful biomarker in the design of future milk formulas for SGA infants.
The strengths of the present study include the longitudinal design, the co-availability of body-composition assessments and of AGA-BRF controls. Study limitations include the relatively small study population, the absence of sampling times in the neonatal phase, and the absence of AGA-FOF controls. Future studies are likely to investigate the potential influence of gut microbiota on circulating GLP-1 and other incretins in early infancy, 13 and thus perhaps on the neonatal programming of appetite and other hypothalamic setpoints.
In conclusion, circulating GLP-1 concentrations were normal in SGA infants at birth, normal in SGA-BRF infants at 4 months but elevated in SGA-FOF infants. It remains to be studied whether elevated GLP-1 concentrations in early infancy have long-term implications, for example, on the hypothalamic control of energy homeostasis and thus on diabetes risk.
